1. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure. 2013 May;6(3):606-19.
2. Masoudi FA, Baillie CA, Wang Y, Bradford WD, Steiner JF, Havranek EP, Foody JM, Krumholz HM. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Archives of internal medicine. 2005 Oct 10;165(18):2069-76.
3. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. The American journal of medicine. 2011 Feb 1;124(2):136-43.
4. Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.
5. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clinical cornerstone. 2001 Jan 1;3(5):50-9.
6. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Archives of Internal Medicine. 2002 Feb 11;162(3):265-70.
7. Huerta C, Varas-Lorenzo C, Castellsague J, Rodriguez LG. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006 Nov 1;92(11):1610-5.
8. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, Sørensen R, Folke F, Buch P, Gadsbøll N, Rasmussen S. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archives of internal medicine. 2009 Jan 26;169(2):141-9.
9. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M.H., Fonarow, G.C., Geraci, S.A., Horwich, T., Januzzi, J.L. and Johnson, M.R., 2013. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), pp.e147-e239.
10. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. New England Journal of Medicine. 1998 Jan 22;338(4):265-6.
11. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Bmj. 2007 Sep 6;335(7618):497.
12. American Diabetes Association. Standards of medical care in diabetes—2016: summary of revisions. Diabetes care. 2016 Jan 1;39(Supplement 1):S4-5.
13. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf. pril 8, 2016. Diakses tanggal 11 Desember 2019.
14. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes care. 2003 Nov 1;26(11):2983-9.
15. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert opinion on pharmacotherapy. 2013 Oct 1;14(15):2047-58.
16. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases. 2014 Jul 1;24(7):689-97.
17. Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Annals of internal medicine. 2002 Sep 3;137(5_Part_1):313-20.
18. Sica DA. Doxazosin and congestive heart failure. Congestive Heart Failure. 2002 May;8(3):178-84.
19. Walsh RA. The effects of calcium-entry blockade on left ventricular systolic and diastolic function. Circulation. 1987 Jun;75(6 Pt 2):V43-55.
20. Vider, E. & Zada, I. The Use of Calcium Channel Blockers in Heart Failure. The Journal for Nurse Practitioners. 2018;15(1):149-150
21. Zhang Y, Cheng Z. Sympathetic inhibition with clonidine prolongs survival in experimental chronic heart failure. International journal of cardiology. 2000 Apr 28;73(2):157-62.
22. Nix, DE. Cardiotoxicity induced by antifungal drugs. Current Fungal Infection Reports. 2014;8(2):129-138
23. Rogers KC, Oliphant CS, Finks SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015 Mar 1;75(4):377-95.